Adjuvant anti-PD-1 antibody treatment in stage III/IV melanoma: real-world experience and health economic considerations.

Peter Koelblinger; Magdalena Hoellwerth; Marie-Therese Dernoscheg; Lukas Koch; Erika Richtig; Marina Wanner; Van-Anh Nguyen; Herwig Ostermann; Johann Bauer; Martin Laimer

doi:10.1111/ddg.14511

Adjuvant anti-PD-1 antibody treatment in stage III/IV melanoma: real-world experience and health economic considerations.

Peter Koelblinger^* (First author), Magdalena Hoellwerth (Co-author), Marie-Therese Dernoscheg, Lukas Koch, Erika Richtig, Marina Wanner, Van-Anh Nguyen, Herwig Ostermann, Johann Bauer (Co-author), Martin Laimer (Last author)

^*Corresponding author for this work

Department of Dermatology and Allergology

Research output: Contribution to journal › Original Article › peer-review

10 Citations (Web of Science)

Original language	English
Pages (from-to)	1186-1198
Journal	JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
Volume	19
Issue number	8
DOIs	https://doi.org/10.1111/ddg.14511
Publication status	Published - 2021

Keywords

IPILIMUMAB
NIVOLUMAB
MULTICENTER
DISSECTION

Access to Document

10.1111/ddg.14511

Cite this

Koelblinger, P., Hoellwerth, M., Dernoscheg, M.-T., Koch, L., Richtig, E., Wanner, M., Nguyen, V.-A., Ostermann, H., Bauer, J., & Laimer, M. (2021). Adjuvant anti-PD-1 antibody treatment in stage III/IV melanoma: real-world experience and health economic considerations. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 19(8), 1186-1198. https://doi.org/10.1111/ddg.14511

@article{7ebef34a161643d085d127a011bb3d4a,

title = "Adjuvant anti-PD-1 antibody treatment in stage III/IV melanoma: real-world experience and health economic considerations.",

keywords = "IPILIMUMAB, NIVOLUMAB, MULTICENTER, DISSECTION",

author = "Peter Koelblinger and Magdalena Hoellwerth and Marie-Therese Dernoscheg and Lukas Koch and Erika Richtig and Marina Wanner and Van-Anh Nguyen and Herwig Ostermann and Johann Bauer and Martin Laimer",

note = "K{\"o}lblinger; Laimer; Bauer; Hoellwerth: Department of Dermatology and Allergology, Paracelsus Medical University, Salzburg, Austria; ident m dt. Version: ID 35135",

year = "2021",

doi = "10.1111/ddg.14511",

language = "English",

volume = "19",

pages = "1186--1198",

journal = "JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT",

issn = "1610-0379",

publisher = "Wiley Verlag ",

number = "8",

}

Koelblinger, P , Hoellwerth, M, Dernoscheg, M-T, Koch, L, Richtig, E, Wanner, M, Nguyen, V-A, Ostermann, H, Bauer, J & Laimer, M 2021, 'Adjuvant anti-PD-1 antibody treatment in stage III/IV melanoma: real-world experience and health economic considerations.', JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, vol. 19, no. 8, pp. 1186-1198. https://doi.org/10.1111/ddg.14511

Adjuvant anti-PD-1 antibody treatment in stage III/IV melanoma: real-world experience and health economic considerations. / Koelblinger, Peter (First author); Hoellwerth, Magdalena (Co-author); Dernoscheg, Marie-Therese et al.
In: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 19, No. 8, 2021, p. 1186-1198.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Adjuvant anti-PD-1 antibody treatment in stage III/IV melanoma: real-world experience and health economic considerations.

AU - Koelblinger, Peter

AU - Hoellwerth, Magdalena

AU - Dernoscheg, Marie-Therese

AU - Koch, Lukas

AU - Richtig, Erika

AU - Wanner, Marina

AU - Nguyen, Van-Anh

AU - Ostermann, Herwig

AU - Bauer, Johann

AU - Laimer, Martin

N1 - Kölblinger; Laimer; Bauer; Hoellwerth: Department of Dermatology and Allergology, Paracelsus Medical University, Salzburg, Austria; ident m dt. Version: ID 35135

PY - 2021

Y1 - 2021

KW - IPILIMUMAB

KW - NIVOLUMAB

KW - MULTICENTER

KW - DISSECTION

U2 - 10.1111/ddg.14511

DO - 10.1111/ddg.14511

M3 - Original Article

C2 - 34255435

SN - 1610-0379

VL - 19

SP - 1186

EP - 1198

JO - JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

JF - JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

IS - 8

ER -